CE Ventures (CEIIF)

CE Ventures, also known as CEIIF, is a Tel Aviv-based venture firm with a strategic orientation toward bridging Israeli technology with Asian healthcare markets. The fund concentrates on life sciences, deep-tech medical devices, and biotech, with the thesis that Israeli innovation in clinical hardware and biology is well suited to Asian healthcare systems whose scale and capital deployment are accelerating. For founders building AI-enabled medical devices, diagnostics, and biotech-adjacent platforms with global ambition, CE Ventures is a relevant if specific fit.

The relevant thesis for AI healthcare founders is straightforward. The fund favors companies whose underlying technology is genuinely scientific or hardware-coupled, where AI is deployed inside imaging, diagnostics, procedural guidance, or biological data analysis, and where Asian markets are a credible commercial target alongside the US and Europe. Pure consumer wellness, lightweight digital health, and pure SaaS plays without a deep clinical anchor are not core.

Check sizes range from $1M to $5M at entry, deployed at Series A and Series B. The fund participates as a co-lead or significant follower in priced rounds, holds reserves for follow-on, and brings strategic relationships with Asian hospital systems, regulatory navigators, and corporate partners that can materially affect a company’s commercial trajectory. Geography of investment is principally Israel, with portfolio companies typically operating globally and pursuing both Western and Asian markets explicitly.

The team brings investment, operational, and cross-border experience, with relationships into Asian pharma, hospital, and regulatory ecosystems built up over years. Board engagement at Series A and Series B tends to focus on regulatory pathway in target markets, commercial partnerships, and downstream financing strategy. The fund operates with patience characteristic of healthcare investing rather than software-style timelines.

Founders should approach CE Ventures when the company is genuinely a life sciences, device, or deep diagnostic business with traction, when regulatory work is mature or progressing well, and when Asian markets are a real part of the strategic plan rather than a vague aspiration. Introductions through Israeli healthtech VCs, hospital collaborators, or operators with cross-border experience are the most efficient path in. The right time to engage is when commercial signals are emerging, the team has thought carefully about international expansion, and the next round is being structured. Founders without a credible Asia thesis should weigh whether a generalist fund might be a better fit. Companies pitching consumer wellness, light SaaS, or pure US-only commercial plans will not find natural alignment. For founders building deep-tech AI healthcare companies who want a partner positioned to facilitate Asian market entry, CE Ventures offers capital and strategic infrastructure that few Israeli funds can match.